Exelixis Cabometyx, Pfizer Sutent Compete In Kidney Cancer Clinical Trial Cabozantinib was found to improve progression-free survival in metastatic renal cell carcinoma. A clinical study for the treatment of metastatic kidney cancer suggested cabozantinib will potentially become a first-line treatment. by Livia Rusu